Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangzhi Yishen Capsule is a traditional Chinese medicine (TCM) therapeutic candidate developed by Lei Yun Shang Pharmaceutical Group for the treatment of diabetic kidney disease (DKD). The drug is specifically indicated for patients with type 2 diabetes mellitus who present with the TCM syndrome of qi-yin deficiency and blood stasis. As a multi-component herbal formulation, it is designed to address the complex pathophysiology of DKD by potentially tonifying vital energy (Qi) and nourishing Yin while promoting blood circulation to resolve stasis. It is currently undergoing Phase II clinical evaluation in China to assess its efficacy and safety in improving renal outcomes and managing symptoms associated with diabetic nephropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangzhi Yishen Capsule.